Co-Authors
This is a "connection" page, showing publications co-authored by ANTHONY PAUL CONLEY and VIVEK SUBBIAH.
Connection Strength
3.157
-
Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes. Clin Cancer Res. 2023 12 01; 29(23):4844-4852.
Score: 0.243
-
The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications. Clin Cancer Res. 2023 11 14; 29(22):4669-4678.
Score: 0.243
-
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. Clin Cancer Res. 2023 08 15; 29(16):2988-3003.
Score: 0.239
-
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.
Score: 0.234
-
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409.
Score: 0.229
-
Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma. Cancers (Basel). 2021 Oct 19; 13(20).
Score: 0.210
-
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Mol Cancer Ther. 2020 05; 19(5):1165-1172.
Score: 0.188
-
Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. Cancers (Basel). 2019 Aug 31; 11(9).
Score: 0.181
-
MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel). 2019 May 15; 11(5).
Score: 0.178
-
Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clin Cancer Res. 2018 08 15; 24(16):3845-3856.
Score: 0.168
-
Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. Curr Oncol Rep. 2018 03 26; 20(5):37.
Score: 0.164
-
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017 12 19; 5(1):100.
Score: 0.161
-
The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. Curr Oncol Rep. 2017 Oct 13; 19(12):78.
Score: 0.159
-
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017 Jun 13; 8(24):39254-39267.
Score: 0.156
-
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430.
Score: 0.148
-
Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities. Orphanet J Rare Dis. 2013 Jul 30; 8:112.
Score: 0.119
-
Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. Curr Probl Cancer. 2021 10; 45(5):100794.
Score: 0.052
-
High-Throughput Architecture for Discovering Combination Cancer Therapeutics. JCO Clin Cancer Inform. 2018 12; 2:1-12.
Score: 0.043
-
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
Score: 0.043